Pipeline

Legal Disclaimer | Site Map | Contact
© 2007 CuraGen Corporation

April 22, 2008
Q1 Earning call

CuraGen Corporation (NASDAQ: CRGN) is a clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer. Strategic alliances forged by CuraGen have resulted in a pipeline of potential therapeutics that is being advanced by the Company's experienced team. CuraGen is currently conducting clinical trials with CR011-vcMMAE, an antibody-drug conjugate being developed for the treatment of melanoma, breast cancer and brain tumors. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its therapeutics toward the market and addressing the unmet medical needs of cancer patients.

Recent News

April 22, 2008
CuraGen Sells Ownership of Belinostat to TopoTarget A/S

April 22, 2008
CuraGen Reports First Quarter 2008 Financial Results

April 9, 2008
CuraGen Advances CR011-vcMMAE into Phase II

Events

April 22, 2008
Q1 Earning call

December 11, 2007
Update on Belinostat

Quotes delayed at least 20 minutes.
Information provided by TurboFeed.